J 2022

Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma

MOEHLER, Markus, Anica HOEGNER, Anna D WAGNER, Radka OBERMANNOVÁ, Maria ALSINA et. al.

Basic information

Original name

Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma

Authors

MOEHLER, Markus (guarantor), Anica HOEGNER, Anna D WAGNER, Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution), Maria ALSINA, Peter THUSS-PATIENCE, van Laarhoven HANNEKE and Elizabeth SMYTH

Edition

European Journal of Cancer, Oxford, Elsevier Science Inc. 2022, 0959-8049

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 8.400

RIV identification code

RIV/00216224:14110/22:00128423

Organization unit

Faculty of Medicine

UT WoS

000892112500002

Keywords in English

Checkpoint inhibitors; Esophageal cancer; Esophagogastric cancer; Her2-positive; Immunotherapy; Gastric cancer; PD-L1; PD-1

Tags

Tags

International impact, Reviewed
Změněno: 31/1/2023 09:19, Mgr. Tereza Miškechová

Abstract

V originále

The new era of immunotherapy is successfully implemented in the treatment of metastatic/locally advanced esophagogastric adenocarcinoma (EGAC), as it has been investi-gated in combinations with/without chemotherapy in human epidermal growth factor receptor 2 (Her2)-positive and Her2-negative tumors. Recent approvals of immune checkpoint inhibi-tors (ICI) enrich the therapeutic landscape in nearly every therapeutic line. Based on CHECKMATE-649, the combination of nivolumab and chemotherapy in first-line therapy of programmed cell death protein 1 (PD-L1)-positive patients with advanced gastroesophageal junction cancer (GEJC), esophageal cancer (EC), and gastric cancer (GC) was approved in Europe for PD-L1 combined positivity score (CPS) >= 5 patients and independently from PD-L1 score in the USA and Asia. Based on KEYNOTE-590, patients with advanced GEJC and EC qualify for the combination of pembrolizumab plus chemotherapy in Europe (CPS > 10) and the USA. For Her2-positive patients, trastuzumab with first-line chemo-therapy plus pembrolizumab has beneficial response rates and resulted in approval in the USA (KEYNOTE-811). In third-line therapy, superior overall survival (OS) was achieved by the administration of nivolumab (approval in Japan, ATTRACTION-02), and pembroli-zumab shows a positive effect on the duration of response (KEYNOTE-059). Questions of resistance to immunotherapy or the role of gender in response to ICI need to be clarified. This review provides an overview of the current approvals of ICI in advanced EGAC and reflects results of relevant phase II/III trials with focus on possible biomarkers, including PD-L1 CPS and microsatellite-instability (MSI) status.